## Edgar Filing: ASELAGE STEVE - Form 4

ASELAGE ST Form 4											
<b>FORM 4</b> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									PPROVAL 3235-0287		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction See In						chang Act o	ge Act of 1934, f 1935 or Sectio	burden hou response	Estimated average burden hours per response 0.5		
1(b).					1						
ASELAGE STEVE Symbol				er Name <b>and</b> Ticker or Trading ARIN PHARMACEUTICAL MRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)(First)(Middle)3. Date of (Month/DC/O BIOMARIN06/22/24PHARMACEUTICAL INC., 10506/22/24DIGITAL DRIVE06/22/24				-				Director 10% Owner X Officer (give title Other (specify below) below) SVP, Chief Business Officer			
				ndment, Date Original h/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
NOVATO, C		(Zip)						Form filed by M Person	More than One Re	eporting	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Dee Executio any	emed	3.	4. Securi nAcquired Disposed (Instr. 3,	ties l (A) o l of (D	or ))	quired, Disposed o 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	f, or Beneficial 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of	
Common Stock	06/22/2009			M <u>(1)</u>	2,500	A	\$0	50,916	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

## Edgar Filing: ASELAGE STEVE - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	\$ 0	06/22/2009		М	2,500	06/22/2009 <u>(2)</u>	(2)	Common Stock	2,500

## **Reporting Owners**

Reporting Owner Name / Address		Relationships					
Di			10% Owner	Officer	Other		
ASELAGE STEVE C/O BIOMARIN PHARMAC 105 DIGITAL DRIVE NOVATO, CA 94949	EUTICAL INC.			SVP, Chief Business Officer			
Signatures							
G. Eric Davis, Attorney-In-Fact	06/24/2009	)					
<u>**</u> Signature of Reporting Person	Date						

\*\*Signature of Reporting Person

## **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v). \*

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Acquisition of shares on regularly scheduled vesting of restricted stock units granted on May 22, 2008.

(2) Original grant vests in four equal installments on June 22, 2009, May 22, 2010, May 22, 2011 and May 22, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.